I don't know what you want to hear man, on the Race Oncology websites it mentions the solubility issues as the reason it ultimately never made it to market. Does it matter if they mention both the M&A activity and the solubility issues at the same time? I would have thought by now we are all somewhat familiar. It's the recent results, and upcoming trials that seem more interesting to me than nitpicking wording from the past.
In saying that, I'm all for holding the company to account and seeking clarification as much as possible - I'm just not sure that this is one of those times where it matters a lot.
And for context, Dr Tillett has certainly mentioned both the M&A and solubility issues in the past, that's how I know about it.
I don't know what you want to hear man, on the Race Oncology...
-
- There are more pages in this discussion • 363 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.70 |
Change
0.050(3.03%) |
Mkt cap ! $289.6M | |||
| Open | High | Low | Value | Volume |
| $1.66 | $1.70 | $1.63 | $181.9K | 109.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 11946 | $1.70 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.75 | 27579 | 4 |
View Market Depth
| Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |